• Home
  • About
  • All Companies
    • Recent
    • Summary Lists
  • Contact

Vilya

  • November 25, 2022
  • New Biotech Startups

Vilya is a spin-out of the University of Washington Institute for Protein Design (IPD), with a platform to design membrane-permeable peptides with high structural accuracy, opening up a new class of medicines that combine the advantages of traditional small-molecule drugs and larger protein therapeutics.

In a paper published in Cell in September 2022 titled “Accurate de novo design of membrane-traversing macrocycles” scientists at IPD describe one element of the research behind Vilya’s foundational technology, which uses computational methods to robustly design membrane-permeable and orally bioavailable peptides with high structural accuracy.

The drug design breakthrough may lead to new medications for a wide variety of health disorders, including cancer, infection, and inflammation. Vilya intends to leverage its platform to focus on previously difficult-to-drug therapeutic targets.

Vilya was co-founded by a team of scientists from the IPD including David Baker, Ph.D. The company was funded $50 million in a Series A round led by ARCH Venture Partners in 2022.


Subscribe for alerts on new companies featured on Startups.Bio


January 25, 2023MxT Biotech
MxT Biotech, a Korea University spin-out, aims to transform cancer immunotherapy, cellular engineering and genome editing with its patented non-viral genome editing technology. The Hydroporator™ is a non-viral microfluidic platform …
November 16, 2022VentureRadar’s Top 100 Emerging Biotech Start-ups Report
Biotechnology is in the midst of a exciting era of innovation, with an ever-expanding toolbox of modalities and approaches spawning development of exciting new vaccines, medicines and therapies. VentureRadar's Top …
November 2, 2022CorriXR Therapeutics
CorriXR Therapeutics is an oncology-focused biotherapeutics developing a novel gene editing platform technology. CorriXR has developed an innovative CRISPR/Cas molecule that disables the genome of a tumor cell but not …
October 6, 2022THERAtRAME
THERAtRAME was founded based on new insights in transfer RNA (tRNA) epitranscriptomics resulting from over a decade of fundamental research at the GIGA Institute (ULiège) and WELBIO. Transfer RNAs mediate …

View all recently featured startups


Tags:

© Copyright 2022. Startups.Bio, powered by VentureRadar.